Reimbursement

Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.

The new report found that widely used prescription drugs increased by an average of 4.2% in 2017, double the general inflation rate of 2.1%.

As the cost of treating the disease has risen, so too have the direct medical care expenses that patients pay out of pocket, as commercial insurers increasingly shift the burden of paying for treatment to patients through higher premiums, deductibles, and co-pays.

David Pope, PharmD, CDE, and chief innovation officer of OmniSYS, and John King, CEO of OmniSYS, discuss some opportunities to leverage cash prescriptions to drive revenue in the pharmacy. 

Community Pharmacy Consultant Bruce Kneeland and Theresa Dickinson, RPh, owner of Melrose Pharmacy in Phoenix, AZ, discusses direct payment options for payers and patients. 

John King, CEO, and David Pope, Chief Innovation Officer, of OmniSYS, discuss how they're tackling reimbursement issues for pharmacies. 

These techs are key players in navigating the complexities of the compliance requirements and training staff.

In 2018, the drugs generated $293 billion in savings, based on a recent AAM report.

When a pharmacist and a pharmacy assistant are indicted on charges of defrauding a government health insurance program and make motions with the relevant federal court to overturn the charges, should they prevail, heading off a trial, or should the matter proceed to trial?

The American Society of Health-System Pharmacists (ASHP) has released a statement opposing the Centers for Medicare and Medicaid Services’ (CMS) proposed cuts to reimbursement for drug purchased through the 340B Drug Pricing Program.

Eyad Farah, Vice President and General Manager, Health Mart Atlas discusses what the company is doing to lower DIR fees for Health Mart pharmacies.

That is the message that pharmacy leaders must send to payers and pharmacy benefit managers.